SpinTech MRI | Karen Holzberger, President & CEO

(Transcription)

Karen Holzberger  0:01  

Hello again, I'm Karen holtzberg. I'm the newly appointed CEO and President of SpinTech MRI. Let me get the clicker here. With that, who are we? We're a software platform that works across the MRI ecosystem that extracts and brings data outputs imaging data outputs to the care teams to make better informed decisions around brain health. And I'm really excited to be at the helm with Dr. Heiki. Dr. Heiki is our chief scientific officer and founder he is well recognized in the in the world of MRI, Willie as the inventor of many of the sequences that doctors and providers are using today, to really start to indicate and treat diseases around Parkinson's, dementia or other movement disorders all around neurology. It's incredible what he's done over the past 40 years with 300 Plus research papers done around these disease states, as well as 19, and almost 20 patents. And it's really excited to bring his lifelong work to market, you know, across the globe and the MRI ecosystem. Let's talk a little bit about like the problems and things that we're tackling. If you think about the prevalence of neurological disorders across the globe, and how they're treated, each year, 10 million patients are diagnosed with Parkinson's. And to give you that example, it's a really difficult disease to start treating within the first five years, as well as identifying there is no single clinical test, there's many different treatment options, incredibly enough, three out of four times they're only getting the answer correct. And when they start doing this, they start in imaging. And this is where we play a role as being the software operating system over the MRI, a neurologist, a primary care physician, the first indication around many of these diseases to order an MRI. And you can see what can happen, the MRI is an extraordinarily powerful tool, diagnostic tool, and the go to tool for these doctors to make these informed decisions and start to develop these care treatment plans. There's this tension happening within the health system that you hear about all the time, the tension to keep these machines running as effectively and efficiently as possible. The neurologists are looking for these data outputs, but they come at a cost and a trade off to each other, you have about 10 minutes to run some of these brain images to get the data output that you need. The quantitative and qualitative output of these microbleeds, these very small nuances found in the imaging, you need to take longer time. And what we've we've been able to develop through Dr. hickeys work. And our company's spin tech is to be able to extract curate, and put together in an output efficiently effectively without compromising the sequence time, or how long that patients in the machine. Really important as the departments that health systems who are, you know, seeing so many patients each and every day, whether it's inpatient in the afternoon, the ambulatory patients during the day, to be able to keep these machines running as efficiently and effectively as possible, and imbalance giving the information to the neurologist to make informed earlier diagnosis with the tools that we're giving them with the imaging data. And so this is where stage comes in. We are a comprehensive brain imaging solution, really thinking about and across the care pathways that we talked about to really help give the doctors the right tools early to make these diagnosis is to improve patient outcomes, the financial outcomes, as well as the clinical outcomes, you know, for our health systems. And what's interesting about this is that because we work across the MRI ecosystem, and what does that mean? Well, it doesn't matter what Mr. The systems are using, whether it's in China, where there's 6000, high field magnets today, in the US where there's 8000 magnets today, whether it's from Philips GE Siemens united, that we've got this ability and the interoperability to be able to extract this data and give that information to the doctors so they can make the right informed choices. I'm excited to say that we are FDA approved, and we've been FDA approved since October of 2021. We've been working with key partners here and I talked a little bit about the market here what's happening. But with that, where we are to be able to actually really kind of put the demand to this market. Our priority today with the funding that we've received. We're in our series A just closing that out a commitment of six and a half million, 5 million has been committed already. But to really start what is happening in the United States around MR. How do we start taking our solutions, putting it in the hands of the neurologist? Our second priority of Hall horizon two is really What we have to do in China, again, as I said, there's 6000, Highfield, Mr. The pressures that the Chinese face is around how much time do they have to scan their patients or revolutes, around Parkinson's disease, they allow four to five minutes per scan. And we have the ability to give them to take 40% of the time off that scan, but still give them the comprehensive information around these disease states, these movement disorders, these brain diseases for that. So you can see the priorities that we have in the global market that continues to grow with three to 6% CAGR every year, really incredible time for us to be to be able to extract this information and give it into the hands of the doctors. Because well, the other problem that's happening is many of these diseases are have a disconnection to how they're treated, whether it's in the early stage, and the diagnosis, and the identification of Parkinson's or other brain disorders, other movement disorders, to the ongoing treatment, because for example, and I talked about this for the US, typically, a Parkinson's patient is imaged four times per year on MRI. So what else can we do to continue to provide that longitudinal record of the imaging data as the brain is kind of, you know, continuing to transform and the information that those neurologists need. And what's interesting for us, as I said, you know, we hit our first FDA of the stage platform for here focusing on neuro our ambitions are continued to get to our we have a SaaS based model today, but continuing to get into public cloud. We also know as we go across the horizontals of the disease state in neurology, we also know that we will continue into neck and spine, which gives us opportunity to use MR, and getting the data outputs for MSK, or muscle skeletal and continuing to go across whether it's the body region or the disease states, as well as the, the, the the regions around the world. Because what's interesting is the fact that, you know, MR is, again, the de facto tool, it's a very powerful diagnostic tool, the tensions that happen between getting the data having the time to get the data, that we were able to do that too, because of our interoperability. So it's really exciting. We get our Neff F, or nips product called crown through FDA approval, hopefully, by the end of the year. That's our goal, which then opens up the market for us not just for the Highfield magnets, but the 1.5 team magnets to so it's a really exciting time for us. And so where are we today, so we've got partnerships with Siemens and GE Healthcare, as well as in the diagnostics and bioscience space with Octave, who was really tackling the ecosystem around multiple sclerosis and Parkinson's. You know, we see ourselves being the imaging data output and reporting for the neurologist for this, our thought leaders and continued early pilots being Yale, University of Maryland, as well as Loma Linda, you know, in the work that we're doing at University of Michigan, it's really a terrific time for us. And then finally, like I had said, which is even though I'm like very early stage, in my role here as the CEO, we're finalizing our Series A funding at six and a half million dollars, five has been committed, which really, we'll focus on, you know, taking Dr. Haigis, you know, research and software platform, and really bring it to market to solve some of the most challenging problems that we see today, around brain health and neurology. It's my personal mission. I didn't really tell you a little bit about myself, but I've been in radiology and enterprise imaging for the past 20 years, and to be a part of what Dr. Heiki has been doing to really solve these issues and solve these, you know, these chronic diseases to make it a little bit better and hearing yesterday, last night's discussion around, you know, American Cancer Society and what we can do to help not the patients today but the patients of tomorrow with this. So thank you very much for the time I appreciate it and have a wonderful conference.